Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

The impact of receptor–receptor interactions in heteroreceptor complexes on brain plasticity

(2014) Kjell Fuxe et al.   Expert Review of Neurotherapeutics

The G Protein-Coupled Receptor Heterodimer Network (GPCR-HetNet) and Its Hub Components

(2014) Dasiel Borroto-Escuela et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Specific Monomer/Dimer Equilibrium of the Corticotropin-releasing Factor Receptor Type 1 Is Established in the Endoplasmic Reticulum

(2014) Anke Teichmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dynamic modulation of FGFR1–5-HT1A heteroreceptor complexes. Agonist treatment enhances participation of FGFR1 and 5-HT1A homodimers and recruitment of β-arrestin2

(2013) Dasiel O. Borroto-Escuela et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

(2013) Adolfo Ramirez-Zamora et al.   Expert Review of Neurotherapeutics

Heteromeric Dopamine Receptor Signaling Complexes: Emerging Neurobiology and Disease Relevance

(2013) Melissa L Perreault et al.   NEUROPSYCHOPHARMACOLOGY

Moonlighting Proteins and Protein–Protein Interactions as Neurotherapeutic Targets in the G Protein-Coupled Receptor Field

(2013) Kjell Fuxe et al.   NEUROPSYCHOPHARMACOLOGY

A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

(2013) Annalisa Pinna et al.   NEUROTOXICITY RESEARCH

Disruption of the mu–delta opioid receptor heteromer

(2012) Brian F. O’Dowd et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A2A/D2 receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling

(2012) Luca Ferraro et al.   BRAIN RESEARCH

Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease

(2012) J. Michael Bostwick et al.   MAYO CLINIC PROCEEDINGS

Dopamine D1–D2 Receptor Heteromer in Dual Phenotype GABA/Glutamate-Coexpressing Striatal Medium Spiny Neurons: Regulation of BDNF, GAD67 and VGLUT1/2

(2012) Melissa L. Perreault et al.   PLoS One

Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1–D2 heteromer formation

(2011) Brian F. O’Dowd et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Adenosine receptor containing oligomers: Their role in the control of dopamine and glutamate neurotransmission in the brain

(2011) Francisco Ciruela et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Fibroblast Growth Factor Receptor 1– 5-Hydroxytryptamine 1A Heteroreceptor Complexes and Their Enhancement of Hippocampal Plasticity

(2011) Dasiel O. Borroto-Escuela et al.   BIOLOGICAL PSYCHIATRY

Dopamine D4 receptor oligomerization - contribution to receptor biogenesis

(2011) Kathleen Van Craenenbroeck et al.   FEBS Journal

On the Existence of a Possible A2A–D2–β-Arrestin2 Complex: A2A Agonist Modulation of D2 Agonist-Induced β-Arrestin2 Recruitment

(2011) Dasiel O. Borroto-Escuela et al.   JOURNAL OF MOLECULAR BIOLOGY

The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease

(2011) A. Tozzi et al.   JOURNAL OF NEUROSCIENCE

Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain

(2011) S González et al.   MOLECULAR PSYCHIATRY

Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance

(2011) Ahmed Hasbi et al.   Molecular Brain

Characterization of the A2AR–D2R interface: Focus on the role of the C-terminal tail and the transmembrane helices

(2010) Dasiel O. Borroto-Escuela et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dopamine D2 and D4 receptor heteromerization and its allosteric receptor–receptor interactions

(2010) Dasiel O. Borroto-Escuela et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Adenosine-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders

(2010) K. Fuxe et al.   CNS Neuroscience & Therapeutics

Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects

(2010) Lin Pei et al.   NATURE MEDICINE

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

(2010) Daniel Marcellino et al.   NEUROBIOLOGY OF DISEASE

Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: Parallel observations from co-transfected human and native cerebral receptors

(2010) Gabriella Aloisi et al.   NEUROPHARMACOLOGY

From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease

(2010) Mark J. Millan   PHARMACOLOGY & THERAPEUTICS

Uncoupling the D1- N- Methyl-D-Aspartate (NMDA) Receptor Complex Promotes NMDA-Dependent Long-Term Potentiation and Working Memory

(2009) Qiang Nai et al.   BIOLOGICAL PSYCHIATRY

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

(2009) Roberto Maggio et al.   CURRENT OPINION IN PHARMACOLOGY

Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function

(2009) Chiara Fiorentini et al.   CURRENT OPINION IN PHARMACOLOGY

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction

(2009) K.A. Stockwell et al.   EXPERIMENTAL NEUROLOGY

Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management

(2009) Angelo Antonini et al.   Expert Review of Neurotherapeutics

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

(2009) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Metabotropic glutamate type 5, dopamine D2and adenosine A2areceptors form higher-order oligomers in living cells

(2009) Nuria Cabello et al.   JOURNAL OF NEUROCHEMISTRY

Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L-DOPA-Induced Dyskinesia

(2009) A. Berthet et al.   JOURNAL OF NEUROSCIENCE

Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling

(2009) D. Rylander et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism

(2009) Bérangère Ballion et al.   NEUROBIOLOGY OF DISEASE

Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease

(2009) Hanna S Lindgren et al.   NEUROPSYCHOPHARMACOLOGY

The discovery of central monoamine neurons gave volume transmission to the wired brain

(2009) Kjell Fuxe et al.   PROGRESS IN NEUROBIOLOGY

Receptor–receptor interactions: A novel concept in brain integration

(2009) Luigi F. Agnati et al.   PROGRESS IN NEUROBIOLOGY

Receptor–receptor interactions within receptor mosaics. Impact on neuropsychopharmacology

(2008) K. Fuxe et al.   BRAIN RESEARCH REVIEWS

Potential therapeutic targets for Parkinson's disease

(2008) Jon Stoessl   EXPERT OPINION ON THERAPEUTIC TARGETS

Identification of Dopamine D1–D3Receptor Heteromers

(2008) Daniel Marcellino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reciprocal Regulation of Dopamine D1 and D3 Receptor Function and Trafficking by Heterodimerization

(2008) C. Fiorentini et al.   MOLECULAR PHARMACOLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity

(2008) Marc Flajolet et al.   NATURE NEUROSCIENCE

Molecular mechanisms of L-DOPA-induced dyskinesia

(2008) Peter Jenner   NATURE REVIEWS NEUROSCIENCE

Dopamine D2 and Adenosine A2A Receptors Regulate NMDA-Mediated Excitation in Accumbens Neurons Through A2A–D2 Receptor Heteromerization

(2008) Karima Azdad et al.   NEUROPSYCHOPHARMACOLOGY

L-DOPA-INDUCED DYSKINESIA AND STEREOTACTIC SURGERY FOR PARKINSON'S DISEASE

(2008) Jorge Guridi et al.   NEUROSURGERY

Heterodimers and Receptor Mosaics of Different Types of G-Protein-Coupled Receptors

(2008) Kjell Fuxe et al.   PHYSIOLOGY

Dichotomous Dopaminergic Control of Striatal Synaptic Plasticity

(2008) W. Shen et al.   SCIENCE